Source comparison
CJC-1295 for Natural GH Elevation Research: Comparison Table
CJC-1295 (with DAC) GHRH analogue. Stimulates pituitary GH release ~6–8 days Once or twice weekly None. Preserves endogenous axis 30–60 mcg/kg subcutaneous Preferred for protocols prioritizing long-term axis preservation and pulsatile dynamics Modified GRF(1-2
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- GHRH analogue. Stimulates pituitary GH release
- ~6–8 days
- Once or twice weekly
- None. Preserves endogenous axis
- 30–60 mcg/kg subcutaneous
- Preferred for protocols prioritizing long-term axis preservation and pulsatile dynamics
- Modified GRF(1-29) (CJC-1295 no DAC)
- ~30 minutes
- 1–3 times daily
- 100–200 mcg per dose
- Preferred when precise pulse timing is required or when avoiding albumin-binding modifications
- Synthetic Growth Hormone (Somatropin)
- Direct GH receptor agonist. Replaces endogenous GH
- ~2–3 hours
- Daily subcutaneous injection
- High. Suppresses pituitary somatotrophs via negative feedback
- 0.15–0.3 mg/kg/week divided into daily doses
- Preferred for acute pharmacological intervention or diagnosed GH deficiency. Not for axis preservation
- GHRP-2 / GHRP-6
- Ghrelin receptor agonist. Stimulates pituitary GH release via different pathway
- 100–300 mcg per dose
- Often combined with GHRH analogues for synergistic effect. Less selective than Ipamorelin
- Ipamorelin
- Selective ghrelin receptor agonist. Stimulates pituitary GH release
- ~2 hours
- 1–2 times daily
- 200–300 mcg per dose
- Preferred GHRP for research due to minimal cortisol/prolactin elevation. Often paired with CJC-1295